U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.1057G>A (p.Glu353Lys) AND Cardiovascular phenotype

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jun 11, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002399518.10

Allele description [Variation Report for NM_000527.5(LDLR):c.1057G>A (p.Glu353Lys)]

NM_000527.5(LDLR):c.1057G>A (p.Glu353Lys)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.1057G>A (p.Glu353Lys)
HGVS:
  • NC_000019.10:g.11110768G>A
  • NG_009060.1:g.26388G>A
  • NM_000527.5:c.1057G>AMANE SELECT
  • NM_001195798.2:c.1057G>A
  • NM_001195799.2:c.934G>A
  • NM_001195800.2:c.553G>A
  • NM_001195803.2:c.676G>A
  • NP_000518.1:p.Glu353Lys
  • NP_000518.1:p.Glu353Lys
  • NP_001182727.1:p.Glu353Lys
  • NP_001182728.1:p.Glu312Lys
  • NP_001182729.1:p.Glu185Lys
  • NP_001182732.1:p.Glu226Lys
  • LRG_274t1:c.1057G>A
  • LRG_274:g.26388G>A
  • LRG_274p1:p.Glu353Lys
  • NC_000019.9:g.11221444G>A
  • NM_000527.4:c.1057G>A
  • c.1057G>A
Protein change:
E185K
Links:
LDLR-LOVD, British Heart Foundation: LDLR_000791;
Molecular consequence:
  • NM_000527.5:c.1057G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.1057G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.934G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195800.2:c.553G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195803.2:c.676G>A - missense variant - [Sequence Ontology: SO:0001583]
Functional consequence:
unknown functional consequence - Comment(s)

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002713861Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Uncertain significance
(Jun 11, 2024)
germlineclinical testing

PubMed (9)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

The molecular basis of familial hypercholesterolemia in The Netherlands.

Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP.

Hum Genet. 2001 Dec;109(6):602-15. Epub 2001 Nov 9.

PubMed [citation]
PMID:
11810272

The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population.

Damgaard D, Larsen ML, Nissen PH, Jensen JM, Jensen HK, Soerensen VR, Jensen LG, Faergeman O.

Atherosclerosis. 2005 May;180(1):155-60. Epub 2005 Jan 12.

PubMed [citation]
PMID:
15823288
See all PubMed Citations (9)

Details of each submission

From Ambry Genetics, SCV002713861.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (9)

Description

The p.E353K variant (also known as c.1057G>A), located in coding exon 7 of the LDLR gene, results from a G to A substitution at nucleotide position 1057. The glutamic acid at codon 353 is replaced by lysine, an amino acid with similar properties. This alteration has been reported in familial hypercholesterolemia (FH) cohorts (Fouchier SW et al. Hum Genet, 2001 Dec;109:602-15; Huijgen R et al. Hum Mutat, 2010 Jun;31:752-60; Chiou KR et al. J Clin Lipidol 2017 Jan;11:386-393.e6). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 26, 2024